NCT06641635RecruitingPhase 3
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Study of Moderated Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 440 (estimated)
- First submitted
- 8 Oct 2024
- Start date
- 19 Nov 2024
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT06641635
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 440
- From 19 Nov 2024 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received other anticancer treatments, including chemotherapy, targeted therapy, or immunotherapy, before concurrent chemoradiotherapy.
- History of prior abdominal or pelvic radiotherapy
Other illness
- Patients who have undergone cervical cancer surgery
- Patients with active infections or fever
- Other severe diseases that may significantly affect clinical trial compliance, such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders.
Other
- FIGO stages IA, IIIA, IIIC2, IVA, or IVB
- FIGO stage IIIC1 with lymph nodes \>2 cm, or with common iliac lymph node metastasis
- Pregnant or breastfeeding women
Who the study is looking for
- The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment
- Age ≥18 and ≤75 years
- FIGO 2018 stage IB1-IIB, IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)
- Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Concurrent weekly cisplatin therapy ± immunotherapy
- Able to undergo brachytherapy
- ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.